Drugs / RGRN-305
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05286567 | Sep 2021 → Aug 2022 | hidradenitis suppurativa | Aarhus University Hospital | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-10-11 | MC2 Therapeutics | Results MC2 Therapeutics Announces Positive Phase 2a Results of Novel HSP90 Inhibitor for Hidradenitis Suppurativa Presented at EADV mc2therapeutics.com ↗
Primary endpoint, HiSCR50 was met at week 16 by 6 out of 10 patients in the MC2-32 group vs. 1 out 5 in the placebo group |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-10-11 | MC2 Therapeutics | MC2 Therapeutics Announces Positive Phase 2a Results of Novel HSP90 Inhibitor for Hidradenitis Suppurativa Presented at EADV mc2therapeutics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RGRN-305 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05286567 ↗ |
| Action | Inhibit | “Heat shock protein 90 inhibitor” NCT05286567 ↗ |
| Route | Oral | “Patients were randomly assigned (2:1) to receive oral RGRN-305, 250-mg tablet, or matching placebo once daily for 16 weeks.” PMID 38055242 ↗ Jan 2024 |